Botox, Dysport, Xeomin, Jeuveau or Nabota — which is best?

None holds an absolute superiority over the others in head-to-head clinical studies when each is dosed according to its own unit convention. Botox (onabotulinumtoxinA, Allergan) has the most published literature by volume — a function of its 20-year market lead, not pharmacological advantage. Dysport (abobotulinumtoxinA, Ipsen) diffuses more broadly and may offer advantages in large muscle fields. Xeomin (incobotulinumtoxinA, Merz) is protein-free, relevant for patients with a history of antibody formation. Jeuveau (Evolus) holds FDA approval for glabellar lines. The appropriate brand for any given patient depends on the indication, anatomical zone and the physician's dosing expertise with that specific formulation.

Which brand dominates each market?

Botox (Allergan/AbbVie) holds the largest global market share by revenue and procedure volume across North America, Western Europe, Brazil and most of Asia-Pacific — driven by its 2002 FDA approval and subsequent decades of physician training. Dysport is the dominant brand in several Eastern European and Latin American markets. Xeomin holds a significant share in Germany and in therapeutic neurology applications globally. In South Korea and parts of South-East Asia, domestically produced toxins such as Botulax (Hugel) and Nabota (Daewoong) have substantial local market presence. In Brazil, Botox, Dysport and Xeomin are the commercially prominent ANVISA-registered options in aesthetic practice.

Are Korean toxins inferior?

Not inherently. The question of inferiority should be assessed against two criteria: manufacturing quality and regulatory approval. Korean pharmaceutical manufacturers subject to MFDS (Ministry of Food and Drug Safety) oversight and international regulatory submissions operate facilities comparable to those in Europe and North America. Nabota (Daewoong), for example, holds FDA approval for glabellar lines in adults — the same standard applied to Botox and Dysport. The relevant clinical question is whether the specific product carries regulatory approval for the market in which it is being administered. In Brazil, patients should confirm ANVISA registration with their physician before any procedure.

Do approvals differ between FDA, EMA and ANVISA?

Yes, and the differences matter clinically. The FDA (USA), EMA (European Union) and ANVISA (Brazil) are independent regulatory agencies that each conduct their own review processes. A product approved by the FDA is not automatically approved by the EMA or ANVISA — separate submissions and approvals are required. Botox, Dysport and Xeomin hold approvals from all three authorities. Jeuveau holds FDA approval but is not EMA-approved as of 2025. Korean formulations vary in their international approval status. A product used in a Brazilian clinic should carry valid ANVISA registration for the indication in question; physicians sourcing product through authorised distributors can provide documentation on request.

Which brands are available in Brazil?

Botox (Allergan/AbbVie), Dysport (Ipsen) and Xeomin (Merz) are commercially available in Brazil with ANVISA registration and are the formulations used in mainstream aesthetic and clinical practice. Other brands marketed internationally may be present in specific channels, but patients are advised to ask their physician to confirm ANVISA registration and authorised distribution for any product used in their treatment. Cold-chain integrity — meaning uninterrupted refrigeration from manufacturer to clinic — is equally important and should be verifiable on request.

Face · Product comparison · International

Which is the best botulinum toxin brand in the world?

Botox, Dysport, Xeomin, Jeuveau, Nabota — each carries a distinct molecular profile, dosing convention and regulatory history. Understanding the differences is the first step to an informed clinical decision.

Book Consultation

No single "best" — what the clinical evidence actually shows

There is no universally superior botulinum toxin brand: the clinical literature consistently demonstrates that onabotulinumtoxinA (Botox/Vistabel, Allergan/AbbVie), abobotulinumtoxinA (Dysport/Azzalure, Ipsen), incobotulinumtoxinA (Xeomin/Bocouture, Merz), prabotulinumtoxinA (Jeuveau, Evolus) and daxibotulinumtoxinA formulations each achieve comparable safety and efficacy profiles when dosed correctly for their respective unit conventions — which are not interchangeable. The question "which is best" therefore reduces to a more precise set of sub-questions: best for which indication, which anatomical zone, which patient profile, and in whose hands?

The global dominance of Botox is largely a function of market history. Allergan received the first FDA approval for glabellar lines in 2002, building a decade-long head start in physician training and patient recognition. That commercial primacy does not translate to pharmacological superiority. Peer-reviewed head-to-head studies published in journals including the Journal of the American Academy of Dermatology and Aesthetic Surgery Journal show that when conversion ratios are respected — generally 1 unit of onabotulinumtoxinA to 2.5–3 units of abobotulinumtoxinA — clinical outcomes are equivalent across the main approved brands.

What does differ meaningfully between formulations:

Diffusion radius — abobotulinumtoxinA (Dysport) diffuses somewhat more broadly than onabotulinumtoxinA at equivalent clinical doses; this can be an advantage in large muscle fields (frontalis, platysma) and a limitation in precision zones (periorbital).
Complexing proteins — incobotulinumtoxinA (Xeomin) is the only approved product free of complexing proteins (haemagglutinins and non-toxic proteins). This is clinically relevant for patients with a documented history of neutralising antibody formation, though such cases remain uncommon.
Onset speed — abobotulinumtoxinA tends to show earlier visible onset (2–5 days) in a subset of patients, though individual variation is substantial.
Storage — incobotulinumtoxinA does not require refrigeration before reconstitution, offering logistical advantages in some clinical settings.

In summary: brand selection is a clinical tool, not a ranking. An experienced injector matches formulation to indication, dosing to anatomy, and adjusts based on individual response over successive sessions.

Ask a question on WhatsApp →

The global landscape: which brands hold which approvals — and what this means for patients

Regulatory approval is the most objective criterion for comparing botulinum toxin brands across markets. Approval by a stringent authority (the US FDA, the European Medicines Agency, or equivalent) confirms that a product has passed controlled efficacy and safety trials for the indications listed on its label. It says nothing about superiority over other approved products — only that the bar was met.

The main brands and their regulatory positions as of 2025–2026:

Botox / Vistabel (onabotulinumtoxinA, Allergan/AbbVie, USA) — FDA-approved; EMA-approved; ANVISA-registered in Brazil. The most studied botulinum toxin globally by cumulative published literature volume. Widely available in Brazil and registered by ANVISA for cosmetic and therapeutic indications.
Dysport / Azzalure (abobotulinumtoxinA, Ipsen, UK/France) — FDA-approved; EMA-approved; ANVISA-registered in Brazil. The second most studied formulation internationally. Unit dosing convention differs from onabotulinumtoxinA — the two are not directly interchangeable by unit count.
Xeomin / Bocouture (incobotulinumtoxinA, Merz, Germany) — FDA-approved; EMA-approved; ANVISA-registered in Brazil. Distinguished by its protein-free formulation. Approved for glabellar lines and several therapeutic indications.
Jeuveau (prabotulinumtoxinA, Evolus, USA) — FDA-approved for glabellar lines in adults; not EMA-approved as of 2025. Regulatory status in Brazil: not confirmed ANVISA-registered for commercial use as of the date of this review — patients seeking treatment in Brazil should confirm current availability with their physician.
Nabota / Botulax (Korean formulations, Daewoong / Hugel) — manufactured in South Korea, with approvals including the Korean FDA (MFDS) and some international markets. Registration status varies by country. Nabota holds FDA approval for glabellar lines. Regarding Brazil: Korean-manufactured botulinum toxins are present in Latin American markets; specific ANVISA registration status for individual Korean products should be verified with the prescribing physician, as the regulatory landscape is updated periodically.

The following formulations are used in Brazil in legitimate clinical practice and are the ones Dr. Thiago Perfeito works with when evaluating treatment options at INTI:

Botox (Allergan/AbbVie)
Dysport (Ipsen)
Xeomin (Merz)

Patients are advised to verify that the product used in any procedure is ANVISA-registered and sourced through authorised distribution channels — a detail worth raising at consultation.

How to choose a botulinum toxin brand — and why the injector matters more than the label

International aesthetic medicine societies — including ISAPS (International Society of Aesthetic Plastic Surgery), ASDS (American Society for Dermatologic Surgery), and IMCAS (International Master Course on Ageing Science) — converge on a consistent position: clinical outcome in botulinum toxin treatment is determined primarily by injector expertise, anatomical knowledge and dosing precision, not by brand selection among the approved products.

This is not a diplomatic hedge. It reflects a structural reality: the approved brands are all manufactured under stringent pharmaceutical controls; they all contain botulinum toxin type A; they are all safe when administered by a trained physician at recommended doses; and they all lose efficacy predictably over the same 3–6 month window. The marginal difference between a correctly dosed Botox and a correctly dosed Dysport in the glabella of the same patient is smaller than the difference between an undertreated glabella and a correctly treated one — regardless of brand.

For patients coming from clinics in Manhattan, Mayfair, Zurich or Singapore, the relevant questions to ask any physician in Brasília are not "which brand do you use?" but rather:

Do you perform a full facial analysis before choosing dose and injection points?
Do you adjust the unit convention for the specific formulation you are using?
Do you document injection maps for continuity of care across sessions?
Is the product sourced through official distributor channels with verified cold-chain integrity?

Regarding Korean toxins specifically: the question of whether they are "inferior" conflates manufacturing origin with regulatory rigour. Korean pharmaceutical manufacturing — particularly companies subject to MFDS oversight and multinational regulatory submissions — operates to standards comparable to European and North American facilities. Nabota, for example, holds FDA approval. The more relevant question is whether the specific product has been approved by the relevant authority for the market in which it is being used. That determination is regulatory, not geographic.

One clinical note worth flagging for patients who report rapid loss of effect: the most common cause is undertreated dose, not antibody formation. Neutralising antibodies do occur but are uncommon in standard cosmetic dosing regimens. A patient whose Botox "stopped working" after two years is far more likely to have experienced progressively conservative dosing than true immunological resistance.

Updated 5 June 2026

Dr. Thiago Perfeito

CRM-DF 23199 · Aesthetic and Regenerative Medicine

Physician with more than 10 years of practice in aesthetic and regenerative medicine. Master's degree in Aesthetic Medicine (2024). International training at Harvard Medical School and Mayo Clinic. Member of ASLMS, A4M, AMS, and NYAS. Practicing in Brasília, Lago Sul.

Learn about Dr. Thiago →

Frequently asked questions about Botulinum toxin — global market

Botox, Dysport, Xeomin, Jeuveau or Nabota — which is best?

None holds an absolute superiority over the others in head-to-head clinical studies when each is dosed according to its own unit convention. Botox (onabotulinumtoxinA, Allergan) has the most published literature by volume — a function of its 20-year market lead, not pharmacological advantage. Dysport (abobotulinumtoxinA, Ipsen) diffuses more broadly and may offer advantages in large muscle fields. Xeomin (incobotulinumtoxinA, Merz) is protein-free, relevant for patients with a history of antibody formation. Jeuveau (Evolus) holds FDA approval for glabellar lines. The appropriate brand for any given patient depends on the indication, anatomical zone and the physician's dosing expertise with that specific formulation.
Which brand dominates each market?

Botox (Allergan/AbbVie) holds the largest global market share by revenue and procedure volume across North America, Western Europe, Brazil and most of Asia-Pacific — driven by its 2002 FDA approval and subsequent decades of physician training. Dysport is the dominant brand in several Eastern European and Latin American markets. Xeomin holds a significant share in Germany and in therapeutic neurology applications globally. In South Korea and parts of South-East Asia, domestically produced toxins such as Botulax (Hugel) and Nabota (Daewoong) have substantial local market presence. In Brazil, Botox, Dysport and Xeomin are the commercially prominent ANVISA-registered options in aesthetic practice.
Are Korean toxins inferior?

Not inherently. The question of inferiority should be assessed against two criteria: manufacturing quality and regulatory approval. Korean pharmaceutical manufacturers subject to MFDS (Ministry of Food and Drug Safety) oversight and international regulatory submissions operate facilities comparable to those in Europe and North America. Nabota (Daewoong), for example, holds FDA approval for glabellar lines in adults — the same standard applied to Botox and Dysport. The relevant clinical question is whether the specific product carries regulatory approval for the market in which it is being administered. In Brazil, patients should confirm ANVISA registration with their physician before any procedure.
Do approvals differ between FDA, EMA and ANVISA?

Yes, and the differences matter clinically. The FDA (USA), EMA (European Union) and ANVISA (Brazil) are independent regulatory agencies that each conduct their own review processes. A product approved by the FDA is not automatically approved by the EMA or ANVISA — separate submissions and approvals are required. Botox, Dysport and Xeomin hold approvals from all three authorities. Jeuveau holds FDA approval but is not EMA-approved as of 2025. Korean formulations vary in their international approval status. A product used in a Brazilian clinic should carry valid ANVISA registration for the indication in question; physicians sourcing product through authorised distributors can provide documentation on request.
Which brands are available in Brazil?

Botox (Allergan/AbbVie), Dysport (Ipsen) and Xeomin (Merz) are commercially available in Brazil with ANVISA registration and are the formulations used in mainstream aesthetic and clinical practice. Other brands marketed internationally may be present in specific channels, but patients are advised to ask their physician to confirm ANVISA registration and authorised distribution for any product used in their treatment. Cold-chain integrity — meaning uninterrupted refrigeration from manufacturer to clinic — is equally important and should be verifiable on request.

Discuss your case with Dr. Thiago Perfeito

Personalised assessment, ANVISA-registered formulations and anatomical dosing precision. Aesthetic & Regenerative Medicine at INTI clinic, Lago Sul, Brasília. CRM-DF 23199.

Book on WhatsApp Browse all procedures